Hatch-Waxman 201

The Hatch-Waxman Act was enacted by Congress to encourage innovation in pharmaceutical research and development, and shorten the time to market for generic drugs. Fish's award-winning life sciences attorneys have developed a four-part webinar series to examine and explain the Act in detail. Last month Chad Shear presented the first program in the series which introduced the Act and discussed the approval process and requirements. A replay of the Hatch-Waxman 101 webinar is available here.

For the second installment of our Hatch-Waxman webinar series, Chad Shear was joined by the head of the firm's regulatory practice, Terry Mahn. Chad and Terry led an in-depth discussion on:

• The value proposition of drug exclusivities.
• Orange Book strategies and hidden dangers.
• Citizen petitions as an adjunct to Hatch-Waxman litigation.
• Preparing for Hatch-Waxman litigation.

This complimentary webinar is perfect for life sciences professionals interested in delving deeper into Hatch-Waxman topics, including strategies for Hatch-Waxman litigation.

To download the PDF slides of this presentation, click here.